Inhibition of specific nf-κb activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Inglés Esteve, Julia ^a   Morales, Mònica ^b   Dalmases, Alba ^a   Garcia Carbonell, Ricard ^a   Jené Sanz, Alba ^c   López Bigas, Núria ^c,d   Iglesias, Mar ^a   Ruiz Herguido, Cristina ^a   Rovira, Ana ^a   Rojo, Federico ^a,e   Albanell, Joan ^a,c   Gomis, Roger R ^b,c   Bigas, Anna ^a   Espinosa, Lluís ^a  

^a HOSPITAL DEL MAR   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e UAM)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; PHARMACOLOGY; PROTEIN 14 3 3; STRATIFIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN;

ACTIVE TRANSPORT; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER INHIBITION; CELL FRACTIONATION; CELL MOTION; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; METABOLISM; METASTASIS; MICROARRAY ANALYSIS; MORTALITY; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR CELL LINE; UPREGULATION;

14-3-3 PROTEINS; ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CLUSTER ANALYSIS; DRUG EFFECTS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HUMANS; METABOLISM; MICE; MORTALITY; NEOPLASM METASTASIS; NF-KAPPA B; PHARMACOLOGY; PROGNOSIS; PROTEIN BINDING; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS;

EID: 84872758096     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038347     Document Type: Article

References (60)

1. de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC, (2010) Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 102: 410-425.
2. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68.
3. Mundy GR, (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593.
4. Kozlow W, Guise TA, (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10: 169-180.
5. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, et al. (2005) Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 5 Supplpp. S46-53.
6. Grivennikov SI, Greten FR, Karin M, (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
7. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, et al. (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960.
8. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, et al. (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129: 1065-1079.
9. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, et al. (2007) NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13: 62-69.
10. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, et al. (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 101: 10137-10142.
11. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr, (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639.
12. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr, (2000) Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19: 1123-1131.
13. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, et al. (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446: 690-694.
14. Biswas DK, Cruz AP, Gansberger E, Pardee AB, (2000) Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 97: 8542-8547.
15. Zhang GJ, Adachi I, (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19: 1427-1432.
16. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, et al. (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature.
17. Sangaletti S, Tripodo C, Ratti C, Piconese S, Porcasi R, et al. (2010) Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res 70: 7764-7775.
18. Holland PM, Miller R, Jones J, Douangpanya H, Piasecki J, et al. (2010) Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 9: 539-550.
19. Tobinick EL, (2003) Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther 25: 2279-2288.
20. Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, et al. (2010) The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 18: 268-281.
21. Fantl WJ, Muslin AJ, Kikuchi A, Martin JA, MacNicol AM, et al. (1994) Activation of Raf-1 by 14-3-3 proteins. Nature 371: 612-614.
22. Zhang R, He X, Liu W, Lu M, Hsieh JT, et al. (2003) AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J Clin Invest 111: 1933-1943.
23. Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, et al. (2002) 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 156: 817-828.
24. Grozinger CM, Schreiber SL, (2000) Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci U S A 97: 7835-7840.
25. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, et al. (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277: 1501-1505.
26. Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, et al. (2006) Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 173: 279-289.
27. Aguilera C, Fernandez-Majada V, Ingles-Esteve J, Rodilla V, Bigas A, et al. (2006) Efficient nuclear export of p65-IkappaBalpha complexes requires 14-3-3 proteins. J Cell Sci 119: 3695-3704.
28. Arenzana-Seisdedos F, Turpin P, Rodriguez M, Thomas D, Hay RT, et al. (1997) Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 110 (Pt 3): 369-378.
29. Huang TT, Miyamoto S, (2001) Postrepression activation of NF-kappaB requires the amino-terminal nuclear export signal specific to IkappaBalpha. Mol Cell Biol 21: 4737-4747.
30. Lodygin D, Hermeking H, (2005) The role of epigenetic inactivation of 14-3-3sigma in human cancer. Cell Res 15: 237-246.
31. Hodgson JG, Malek T, Bornstein S, Hariono S, Ginzinger DG, et al. (2005) Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. Cancer Res 65: 9695-9704.
32. Zurita M, Lara PC, del Moral R, Torres B, Linares-Fernandez JL, et al. (2010) Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 10: 217.
33. Horie-Inoue K, Inoue S, (2006) Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers. Semin Cancer Biol 16: 235-239.
34. Gundem G, Perez-Llamas C, Jene-Sanz A, Kedzierska A, Islam A, et al. (2010) IntOGen: integration and data mining of multidimensional oncogenomic data. Nat Methods 7: 92-93.
35. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005-1009.
36. Rivas MA, Tkach M, Beguelin W, Proietti CJ, Rosemblit C, et al. (2010) Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation. Breast Cancer Res Treat 122: 111-124.
37. Nicolini A, Carpi A, (2009) Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev 29: 436-471.
38. Liu M, Sakamaki T, Casimiro MC, Willmarth NE, Quong AA, et al. (2010) The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res 70: 10464-10473.
39. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466.
40. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296.
41. Iliopoulos D, Hirsch HA, Struhl K, (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139: 693-706.
42. Merkhofer EC, Cogswell P, Baldwin AS, (2010) Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene 29: 1238-1248.
43. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, et al. (2007) Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67: 2396-2401.
44. Sung B, Cho SG, Liu M, Aggarwal BB, (2010) Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of RANKL signaling. Int J Cancer.
45. Su CH, Zhao R, Zhang F, Qu C, Chen B, et al. (2010) 14-3-3{sigma} exerts tumor suppressor activity mediated by regulation of COP1 stability. Cancer Res.
46. Chan SY, To KF, Leung SF, Yip WW, Mak MK, et al. (2010) 14-3-3sigma expression as a prognostic marker in undifferentiated nasopharyngeal carcinoma. Oncol Rep 24: 949-955.
47. Che XH, Chen H, Xu ZM, Shang C, Sun KL, et al. (2010) 14-3-3epsilon contributes to tumour suppression in laryngeal carcinoma by affecting apoptosis and invasion. BMC Cancer 10: 306.
48. Macdonald N, Welburn JP, Noble ME, Nguyen A, Yaffe MB, et al. (2005) Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3. Mol Cell 20: 199-211.
49. Liu ZG, Hsu H, Goeddel DV, Karin M, (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87: 565-576.
50. Espinosa L, Ingles-Esteve J, Robert-Moreno A, Bigas A, (2003) IkappaBalpha and p65 regulate the cytoplasmic shuttling of nuclear corepressors: cross-talk between Notch and NFkappaB pathways. Mol Biol Cell 14: 491-502.
51. Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D, (2005) Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 44: 51-59.
52. R-Development-Core-Team (2010) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
53. Gundem G, Lopez-Bigas N, (2012) Sample level enrichment analysis unravels shared stress phenotypes among multiple cancer types. Genome Med 4: 28.
54. Bengtsson H, Simpson K, Bullard J, Hansen K, (2008) A generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory. Tech Report #745 Department of Statistics, University of California, Berkeley.
55. Schaefer J, Opgen-Rhein R, Zuber V, Duarte Silva AP, Trimmer K, (2010) corpcor: Efficient Estimation of Covariance and (Partial) Correlation. R package version 1.5.1.
56. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.
57. Perez-Llamas C, Lopez-Bigas N, (2011) Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS One 6: e19541.
58. Hubbard TJ, Aken BL, Ayling S, Ballester B, Beal K, et al. (2009) Ensembl 2009. Nucleic Acids Res 37: D690-697.
59. Therneau T, (2009) survival: Survival analysis, including penalised likelihood. R package version 235-8.
60. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.